Search clinical trials for: PF-05212384

Total 1299 results

Pfizer

Completed

OPEN LABEL, 2-PERIOD STUDY, TO COMPARE BIO-AVAILABILITY OF 2 DIFFERENT FORMULATIONS OF PF-05221304 IN HEALTHY ADULTS

Healthy

United States
Pfizer

Withdrawn

A Study Of Gastrointestinal Tolerability Of PF05212389 In Obese Subjects

Obesity
Pfizer

Completed

Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA) (MIRNA)

Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis With Liver Fibrosis

Hong Kong, United States, Taiwan, Puerto Rico, China, Canada, Korea, Republic of, Bulgaria, Japan, India, Poland, Slovakia
Pfizer

Completed

Single-dose Study of [14C]PF-05221304 Metabolism and Excretion in Healthy Adult Male Subjects

Healthy

United States
Pfizer

Completed

A Single and Multiple Dose Study of PF-05221304 in Healthy Japanese Adults

Healthy

Japan
Pfizer

Completed

Single Dose, Repeated Dose, and Conditional Food Effect Study of PF-05221304 in Healthy Subjects

Normal Healthy

United States
Pfizer

Completed

A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Inhaled Doses Of PF-05212372.

Pharmacokinetics | Safety | Phase 1 | Single Dose | Toleration

Belgium
Pfizer

Completed

Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis

Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis

United States, Canada
Pfizer

Completed

Study of PF-05221304 in Subjects With Varying Degrees of Hepatic Impairment

Hepatic Impairment

United States, Belgium, Czechia, Slovakia
Pfizer

Completed

Evaluation of Pharmacokinetic Drug Drug Interaction Between PF-05221304 And PF-06865571 In Healthy Adult Subjects

Healthy

Belgium
Pfizer

Completed

A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.

Non-Alcoholic Fatty Liver Disease (NAFLD)

United States
Pfizer

Completed

A Study To Examine The Distribution Of PF-05212377 In The Brain Of Healthy Volunteer Subjects Using Positron Emission Tomography And A Radioactive Tracer Following Oral Administration Of One Dose Of PF-05212377

Healthy

United States
Wyeth is now a wholly owned subsidiary of Pfizer
Pfizer

Completed

Study Evaluating Multiple Doses Of GSI-953 Within The Elderly Population

Healthy

United States
Pfizer

Completed

Multiple Ascending Dose Study To Assess Safety, Tolerability And Pharmacokinetics Of PF-05212377 (SAM-760) (MAD)

Healthy

France
Pfizer

Completed

Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)

Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis

United States, Israel, Taiwan, Canada, Australia, Poland
Pfizer
Yale University

Completed

This Study Will Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding In Brain Using PET (Positron Emission Tomography) In Healthy Volunteers

Healthy

United States
Pfizer
Yale University

Completed

To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding In Brain Using PET (Positron Emission Tomography) In Healthy Volunteers (3193A1-1103)

Healthy

United States
Columbia University
Pfizer

Withdrawn

Effects of ACC Inhibitor on Lipid and Lipoprotein Metabolism

NASH (Nonalcoholic Steatohepatitis) | NAFLD (Nonalcoholic Fatty Liver Disease)
Pfizer

Terminated

Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil

Alzheimer's Disease

United States, Spain, Canada, United Kingdom, Germany, Chile, France
Pfizer

Completed

Investigation Of The Metabolism, And Excretion Of [14c]-PF-05212384 In Healthy Male Volunteers

Healthy

United Kingdom
Institut Curie
National Cancer Institute, France; Fondation ARC

Terminated

PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML) (LAM-PIK)

Acute Myeloid Leukemia, in Relapse | Therapy-related Acute Myeloid Leukemia and Myelodysplastic Syndrome | de Novo Acute Myeloid Leukemia at Diagnostic

France
Pfizer

Completed

Study of PF-05212384 (Also Known as PKI-587)Administered Intravenously To Subjects With Solid Tumors (B2151001)

Neoplasms

United States, Spain, United Kingdom
Pfizer

Terminated

A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer

Endometrial Neoplasms

United States, Canada, Spain, United Kingdom, Japan, Russian Federation, Poland, Australia
Dana-Farber Cancer Institute
Pfizer

Recruiting

Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors

Pancreatic Cancer | Solid Tumors | Lung Cancer Squamous Cell | Head & Neck Cancer

United States
Antev Ltd.

Completed

A Study of Parenterally-administered Teverelix TFA in Healthy Male Volunteers

Healthy

United Kingdom
Pfizer

Terminated

Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer

Advanced Cancer

Italy, United States, Canada, Spain
Pfizer

Completed

A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)

Neoplasm

United States, Spain, Canada, Italy, United Kingdom
Cristiana Sessa

Completed

Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor (IOSI-NDU-001)

Breast Cancer | NSCLC | Endometrial Cancer | Ovary Cancer | Small Cell Lung Cancer (SCLC) | Head and Neck (HNSCC)

Switzerland
Pfizer

Terminated

A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer

Metastatic Colorectal Carcinoma

United States, Canada, Spain
Pfizer

Completed

To Calculate the Pharmacokinetics (Concentration of Compound in and Rate of Excretion From the Blood) Following a Very Low Dose of Compound Which Will Not Have Any Pharmacological Activity

Healthy

United Kingdom
Pfizer

Terminated

A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Korea, Republic of, United States, Japan, Spain
Pfizer

Completed

A Drug-Drug Interaction Study Between PF-06882961 and PF-06865571 in Healthy Adult Participants and Overweight Adults or Adults With Obesity Who Are Otherwise Healthy

Healthy Volunteer

United States
Pfizer

Completed

A DRUG-DRUG INTERACTION STUDY BETWEEN PF-06650833 AND PF-06651600 FOLLOWING MULTIPLE DOSES IN HEALTHY PARTICIPANTS

Healthy

United States
Pfizer

Completed

A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia

Schizophrenia

United States
University of Florida
Pfizer

Terminated

Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002)

Non-Small Cell Lung Cancer

United States
University of Florida

Completed

Potato Fiber and Gastrointestinal Function: Phase 3

Gastrointestinal Symptoms | Stool Frequency | Gastrointestinal Transit Time

United States
Pfizer

Completed

A Study to Understand the Effect of Tablet Formulation and Food on PF-06821497 in Healthy Adult Participants.

Healthy

United States
Pfizer

Completed

A First-in-human Study of Multiple Doses of Topically Administered PF-07295324 and PF-07259955

Healthy

United States
Pfizer

Completed

A Study To Assess The Safety Of PF-06342674 In Healthy Volunteers

Healthy

United States
Pfizer

Completed

Study To Evaluate Safety, Tolerability, And Pharmacokinetics Of PF-06473871 In Normal Healthy Adults

Healthy

Belgium
Pfizer

Completed

A Study To Observe Safety And Blood Concentrations Of PF-06412562 During And Following The Oral Administration Of Multiple Doses Of PF-06412562 In Healthy Adult Volunteers

Healthy

United States
Pfizer

Completed

A Study To Observe Safety And Concentrations Of PF-05297909 And Proteins In Both Blood And Cerebrospinal Fluid After A Single Dose Of PF-05297909 In Healthy Adults

Healthy

United States
Pfizer

Recruiting

A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

Atopic Dermatitis

United States, Canada
Pfizer

Withdrawn

A Study To Examine The Safety And Efficacy Of PF-00610355 In Moderately Asthmatic Subjects (A7881006)

Respiratory Tract Diseases | Bronchial Diseases | Lung Diseases, Obstructive | Asthma, Bronchial
Pfizer

Not yet recruiting

A Study to Learn How the Medicine Called [14C] PF-06821497 is Taken up Into and Removed From the Body.

Healthy Participants
Pfizer

Completed

A Study to Understand How the Study Medicine (PF-07081532) is Processed and Eliminated in Healthy Men

Healthy Participants

Netherlands
Pfizer

Completed

A Study To Observe Safety And Blood Concentrations Of PF-06649751 During And Following The Oral Administration Of Multiple Doses Of PF-06649751 In Healthy Adult Western and Japanese Volunteers

Healthy

United States
Pfizer

Completed

A Study To Observe Safety And Blood Concentrations Of PF-04995274 During And Following the Administration of Multiple Doses Of PF-04995274 In Healthy Adult And Healthy Elderly Volunteers.

Healthy

United States
Pfizer

Recruiting

A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

United States
Wyeth is now a wholly owned subsidiary of Pfizer
Pfizer

Completed

Study Evaluating The Coadministration of Begacestat And Donepezil

Healthy Subjects

United States

3

Subscribe